Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

"Biotech investors should be worried about interest rates rising, not repatriation....

Because higher interest rates diminishes the present value of biotech when compared to future returns minus increased interest rates...."

Traderbx, I don't think your assessment is accurate. The companies that should be worried most about higher interest rates are those that have become reliant on low interest rates to take out debt at a low cost. Most biotechs, particularly smaller ones like ADXS, have little to no debt on their balance sheet so they are not reliant on cheap borrowing costs. ADXS has around $130 million in cash, so at the margin, higher rates will give ADXS more interest on its cash.